deltatrials

Metastatic pancreatic adenocarcinoma Trials in Seattle, United States

Conditions / Metastatic pancreatic adenocarcinoma / Seattle, United States

Metastatic pancreatic adenocarcinoma is a medical condition with active clinical research programs worldwide.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID Title Status Phase
NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer COMPLETED PHASE3
NCT02890355 FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer ACTIVE_NOT_RECRUITING PHASE2
NCT06998940 Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations RECRUITING PHASE3
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT07409272 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer RECRUITING
NCT04233866 Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread ACTIVE_NOT_RECRUITING PHASE2
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT04548752 Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations ACTIVE_NOT_RECRUITING
NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer ACTIVE_NOT_RECRUITING PHASE2

Related Pages